Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

BSR_14_0175_A4_S56

— · A

ad1a4a33-8469-5509-b908-bf21456b2798

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ADIPOGENESIS+0.480
  • MYOGENESIS+0.440
  • UV_RESPONSE_DN+0.420
  • TNFA_SIGNALING_VIA_NFKB+0.400
  • HEDGEHOG_SIGNALING+0.330
  • FATTY_ACID_METABOLISM+0.320
  • TGF_BETA_SIGNALING+0.320
  • COAGULATION+0.310
  • BILE_ACID_METABOLISM+0.300
  • COMPLEMENT+0.280

Top 10 suppressed

  • MYC_TARGETS_V2-0.610
  • E2F_TARGETS-0.590
  • MYC_TARGETS_V1-0.580
  • G2M_CHECKPOINT-0.540
  • UNFOLDED_PROTEIN_RESPONSE-0.430
  • DNA_REPAIR-0.360
  • MTORC1_SIGNALING-0.340
  • ESTROGEN_RESPONSE_EARLY-0.290
  • ESTROGEN_RESPONSE_LATE-0.270
  • PROTEIN_SECRETION-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A1FE-06A-11R-A213-07
breast-umap@18
—A0.862
2SRR8518186
breast-umap@18
—A0.847
3SRR29022842
breast-umap@18
—A0.845
4SRR1313091
breast-umap@18
—A0.840
5SRR8392887
lung-landscapes@6
—cohortA10.837
6TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.834
7TCGA-AC-A6IX-01A-12R-A32P-07
breast-umap@18
—A0.834
8TCGA-D8-A27I-01A-11R-A16F-07
breast-umap@18
—A0.833
9TCGA-D8-A1JU-01A-11R-A13Q-07
breast-umap@18
—A0.832
10SRR8942951
bladder-landscape@3
——0.831

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ADIPOGENESIS0.480Inavolisib— uncovered
MYOGENESIS0.440Inavolisib— uncovered
UV_RESPONSE_DN0.420Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
HEDGEHOG_SIGNALING0.330Inavolisib— uncovered
FATTY_ACID_METABOLISM0.320Inavolisib— uncovered
TGF_BETA_SIGNALING0.320Inavolisib— uncovered
COAGULATION0.310Binimetinib— uncovered
BILE_ACID_METABOLISM0.300Inavolisib— uncovered
COMPLEMENT0.280Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.260Inavolisib— uncovered
ANGIOGENESIS0.250Remibrutinib— uncovered
HEME_METABOLISM0.250Temsirolimus— uncovered
HYPOXIA0.230Idelalisib— uncovered
NOTCH_SIGNALING0.230Inavolisib— uncovered
APICAL_JUNCTION0.210Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.210Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.190Idelalisib— uncovered